title: Ginsenoside metabolite compound K stimulates glucagon-like peptide-1 secretion in NCI-H716 cells via bile acid receptor activation.
abstract: Compound K (CK) is a major metabolite of ginsenosides that is absorbed. CK has antidiabetic effects, although the mechanisms underlying the effects of CK have not fully been known. To elucidate the mechanisms underlying the antidiabetic effects of CK, we studied the effects of CK on GLP-1 secretion from NCI-H716 cells, and explored the mechanisms underlying CK-induced GLP-1 secretion. Treatment of NCI-H716 cells with 10, 50, and 100 μM CK significantly increased GLP-1 secretion, and intracellular Ca²⁺ and cAMP levels in a dose-dependent manner. Transfection of NCI-H716 cells with siRNA specific to α-gustducin and siRNA specific to TAS1R3 had no effect on CK-induced GLP-1 secretion and Ca²⁺ increase. However, transfection of NCI-H716 cells with TGR5-specific siRNA significantly inhibited CK-induced GLP-1 secretion and the increase in Ca²⁺ and cAMP levels. Moreover, CK showed human TGR5 agonist activity in CHO-K1 cells transiently transfected with human TGR5. Our data provide a novel mechanism of CK for antidiabetic effects. Moreover, the findings might suggest that CK is a potential agent that has multiple biological functions in the body via GLP-1 secretion and TGR5 activation.
authors.affiliation: Division of Metabolism and Functionality Research, Korea Food Research Institute, 62 Road-1201, Anyang-Pangyo-ro, Bundang-gu, Sungnam-si, Kyonggi-do, 463-746, Korea.
authors.forename: Kyong
authors.initials: K
authors.lastname: Kim
authors.forename: Min
authors.initials: M
authors.lastname: Park
authors.forename: Yu Mi
authors.initials: YM
authors.lastname: Lee
authors.forename: Mee Ra
authors.initials: MR
authors.lastname: Rhyu
authors.forename: Hye Young
authors.initials: HY
authors.lastname: Kim
mesh_terms: D000818:Animals; D016466:CHO Cells; D020013:Calcium Signaling / Q000187:drug effects; D002460:Cell Line; D045744:Cell Line, Tumor; D003412:Cricetulus; D000242:Cyclic AMP / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D019858:Enteroendocrine Cells / Q000187:drug effects* / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D020868:Gene Silencing; D036145:Ginsenosides / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology*; D052216:Glucagon-Like Peptide 1 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D051379:Mice; D034741:RNA, Small Interfering; D043562:Receptors, G-Protein-Coupled / Q000819:agonists* / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D011994:Recombinant Proteins / Q000737:chemistry / Q000378:metabolism; D015290:Second Messenger Systems / Q000187:drug effects*; D055571:Secretory Pathway / Q000187:drug effects*
chemical_list: D000242:Cyclic AMP; D036145:Ginsenosides; D052216:Glucagon-Like Peptide 1; D007004:Hypoglycemic Agents; D034741:RNA, Small Interfering; D043562:Receptors, G-Protein-Coupled; D011994:Recombinant Proteins; C473772:GPBAR1 protein, human; C112772:ginsenoside compound K